1,501 results on '"Walewska A"'
Search Results
152. Improving Fmoc Solid Phase Synthesis of Human Beta Defensin 3
- Author
-
Walewska, Aleksandra, primary, Kosikowska-Adamus, Paulina, additional, Tomczykowska, Marta, additional, Jaroszewski, Bartosz, additional, Prahl, Adam, additional, and Bulaj, Grzegorz, additional
- Published
- 2022
- Full Text
- View/download PDF
153. Nutritional Status Indicators as Predictors of Postoperative Complications in the Elderly with Gastrointestinal Cancer
- Author
-
Ścisło, Lucyna, primary, Bodys-Cupak, Iwona, additional, Walewska, Elżbieta, additional, and Kózka, Maria, additional
- Published
- 2022
- Full Text
- View/download PDF
154. WIEDZA I DEKLAROWANE POSTAWY RODZICÓW WOBEC SZCZEPIEŃ OCHRONNYCH DLA DZIECI W WARSZAWIE I TALLINIE
- Author
-
Małgorzata Klotško, Bożena Walewska-Zielecka, Dominik Olejniczak, and Joanna Skonieczna
- Subjects
szczepienia ochronne, zachowania zdrowotne, polska, estonia, vaccination, health behaviors, poland, estonia. ,Education ,Sports ,GV557-1198.995 ,Medicine - Abstract
Klotško Małgorzata, Walewska-Zielecka Bożena, Olejniczak Dominik, Skonieczna Joanna. Wiedza i deklarowane postawy rodziców wobec szczepień ochronnych dla dzieci w Warszawie i Tallinie = Knowledge and declared attitude of parents to protective vaccination for children in Warsaw and Tallin. Journal of Education, Health and Sport. 2015;5(12):89-98. ISSN 2391-8306. DOIhttp://dx.doi.org/10.5281/zenodo.35011 http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%2812%29%3A89-98 http://pbn.nauka.gov.pl/works/676933 Formerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011–2014http://journal.rsw.edu.pl/index.php/JHS/issue/archive Deklaracja. Specyfika i zawartość merytoryczna czasopisma nie ulega zmianie. Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., że w roku 2014 nie będzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktów co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r. The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014). © The Author (s) 2015; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 25.09.2015. Revised 25.10.2015. Accepted: 08.12.2015. WIEDZA I DEKLAROWANE POSTAWY RODZICÓW WOBEC SZCZEPIEŃ OCHRONNYCH DLA DZIECI W WARSZAWIE I TALLINIE KNOWLEDGE AND DECLARED ATTITUDE OF PARENTS TO PROTECTIVE VACCINATION FOR CHILDREN IN WARSAW AND TALLIN Małgorzata Klotško1, Bożena Walewska-Zielecka2, Dominik Olejniczak2, Joanna Skonieczna2 1 Absolwentka kierunku Zdrowie Publiczne Wydział Nauki o Zdrowiu Warszawski Uniwersytet Medyczny 2 Warszawski Uniwersytet Medyczny Zakład Zdrowia Publicznego ul. Banacha 1a, 02-097 Warszawa Adres do korespondencji: dr hab. n. med. Bożena Walewska- Zielecka Warszawski Uniwersytet Medyczny Zakład Zdrowia Publicznego ul. Banacha 1a, 02-097 Warszawa Tel: 22 599 21 80 Fax: 22 599 21 81 Słowa kluczowe: szczepienia ochronne, zachowania zdrowotne, Polska, Estonia. Keywords: vaccination, health behaviors, Poland, Estonia. Streszczenie Wprowadzenie Szczepienia, jako jedno ze szczytowych osiągnięć w medycynie stanowią istotny element realizowania polityki zdrowotnej na szczeblu krajowym I globalnym. Regularne uodparnianie dzieci oraz ludzi dorosłych poprawiło jakość i przedłużyło długość życia. Ponadto szczepienia wyeliminowały ospę prawdziwą oraz przyczyniły się do ograniczenia występowania niektórych chorób takich jak polio, świnki czy tężca. Szczepienia zaliczane są do profilaktyki swoistej pierwszego rzędu, która ma za zadanie wpływać na jeden z trzech elementów łańcucha epidemicznego - na wrażliwą populację. Materiał i metody Materiał stanowiło 231 osób rodziców dzieci objętych obowiązkowymi szczepieniami ochronnymi w Warszawie i Tallinie. Wśród ankietowanych znalazły się 173 oraz 58 mężczyzn.. Badanie było przeprowadzone przy użyciu komputera CAWI (ang. Computer-Assisted Web Interview) oraz metodą papierową PAPI (ang. Paper nad Pencil Interview). Do obliczeń korelacji zastosowano test Chi, zaś za poziom istotności przyjęto wartość 0,05. Wyniki Po zastosowaniu metody top2boxes wynika, że w Estonii 30% wierzy w bezpieczeństwo szczepionek, natomiast 70% nie. W Polsce wynik ten kształtuje się odpowiednio na poziomie 38% i 62%. Po zastosowaniu metody top2boxes wynika, że w Estonii 48% badanych widzi w pormowaniu szczepień interes producentów, natomiast 52% nie zgadza się z tym. Natomiast w Polsce na korzyści koncernów wskazuje 59% i 41 % zaprzecza tej teorii. Po zastosowaniu metody top2boxes okazuje się, że w Estonii 84% badanych popiera dobrowolność szczepień, natomiast 15% jest przeciwnych. Natomiast w Polsce jest 65% zwolenników dobrowolności szczepień i 35 % jej przeciwników. Wnioski Rodzice w Estonii i Polsce są świadomi zalet wypływających ze szczepienia dzieci. Może świadczyć o tym udzielenie przez większość ankietowanych pozytywnych odpowiedzi na pytanie 1,2 i 3. Niestety większość z nich nie posiada wiedzy na temat największego osiągnięcia szczepień jakim jest eradykacja ospy prawdziwej w 1980 roku. Może to świadczyć o braku informacji na ten temat ze strony instytucji zajmujących się ochroną zdrowia jak i samego personelu medycznego, szczególnie lekarzy rodzinnych. Rodzice dzieci w Polsce i Estonii nie są wystarczająco informowani na temat wpływu szczepień na zdrowie dziecka. Świadczy o tym zaznaczenie przez większość respondentów pozytywnych odpowiedzi na pytanie 4, 5, i 6. W celu poprawy tej sytuacji należy edukować społeczeństwo poprzez rzetelne kampanie społeczne. Bardzo dużą role powinien odgrywać tutaj personel medyczny, a szczególnie położne, lekarze rodzinni i pediatrzy. Abstract Introduction. Vaccination as one of the top achievements in medicine is an important part of implementing health policy at the national and global levels. Regular immunization of children and adults improved quality of life and extended its expectancy. In addition, inoculation eliminated smallpox and have contributed to reducing the incidence of certain diseases such as polio, mumps and tetanus. Vaccination is classified as specific first order prevention which affects one of the three components of an epidemic chain - the sensitive population. Material and methods The material consisted of 231 persons (parents of children) covered by the mandatory vaccinations in Warsaw and in Tallinn (Estonia). Among those surveyed were 173 and 58 men. The study was conducted using a computer CAWI (Computer-Assisted Web Interview) approach and paper PAPI (Paper on Pencil Interview) one. For the calculation of correlation a Chi test was used, and a level of significance was set at 0.05. Results After applying the top2boxes method following results appeared. In Tallinn 30% of respondents believe in the safety of vaccines, while 70% do not. In Warsaw, these results are respectively 38% and 62%. When it comes to promoting of vaccination there are 48% of respondents in Estonia who see the interest of vaccine producers in its promoting, while 52% of them disagree with that. Whereas in Poland 59% of them are for the benefit of corporations and 41% deny this theory. Differences are seen in regard of the voluntary vaccination. It appears that in Estonia there are 84% of respondents who support its voluntariness, while 15% are opposed. In Poland it is 65% as proponents of vaccination voluntariness and 35% as opponents of it. Conclusions Parents in Estonia and Poland are aware of the advantages arising from the vaccination of children. It may indicates from positive responses to the initial three questions of the majority of respondents. Unfortunately most of them do not have knowledge about the greatest achievement of vaccination which is the eradication of smallpox in 1980. This may indicate a lack of information from the institutions dealing with the health care and the medical staff, especially family doctors. Parents of children in both countries are not sufficiently informed about the impact of vaccination on the health of the child. Evidence of this is selection of positive answers to following three questions by the majority of respondents. In order to improve this situation should educate the public should be educated by reliable social campaigns. A very big role here should be played by medical personnel, particularly midwives, family doctors and pediatricians.
- Published
- 2015
155. Zakaz handlu ludźmi z perspektywy systemu ochrony praw człowieka
- Author
-
Milena J. Sokołowska-Walewska
- Published
- 2021
156. Patients et analystes « dans le même bateau » : traumas collectifs du nazisme et du stalinisme en psychanalyse
- Author
-
Katarzyna Walewska
- Subjects
Psychiatry and Mental health ,Clinical Psychology - Abstract
En m’appuyant sur des vignettes cliniques, je presente differentes facettes de la souffrance psychique profonde comme l’angoisse de l’extermination, la phobie catastrophique, la culpabilite excessive, la degradation morale (introjection inconsciente du personnage de collaborateur-denonciateur), les traumatismes dus a une domination du principe de realite sur le principe de plaisir, l’annihilation du respect humain, le syndrome de victime du systeme. Ces aspects operent aussi bien dans la destinee des patients que dans celle de l’analyste.
- Published
- 2021
157. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
- Author
-
Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander R. Coltoff, Matthew S. Davids, Peter O. Baker, Lori Leslie, Kerry A. Rogers, John N. Allan, Raul Cordoba, Alberto Lopez-Garcia, Darko Antic, John M. Pagel, Nicolas Martinez-Calle, José Antonio García-Marco, Jose-Ángel Hernández-Rivas, Fatima Miras, Catherine C. Coombs, Anders Österborg, Lotta Hansson, Amanda N. Seddon, Javier López Jiménez, Matthew R. Wilson, Dima El-Sharkawi, Daniel Wojenski, Shuo Ma, Talha Munir, Susana Valenciano, Erlene Seymour, Paul M. Barr, Jeffrey Pu, Piers E. M. Patten, Guilherme F. Perini, Scott F. Huntington, Helen Parry, Suchitra Sundaram, Alan Skarbnik, Manali Kamdar, Ryan Jacobs, Harriet Walter, Renata Walewska, Angus Broom, Sonia Lebowitz, Krista M. Isaac, Craig A. Portell, Inhye E. Ahn, Chaitra S. Ujjani, Mazyar Shadman, Sigrid S. Skånland, Elise A. Chong, and Anthony R. Mato
- Subjects
Adult ,Male ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,MEDLINE ,Improved survival ,Antiviral Agents ,Biochemistry ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Aged ,Retrospective Studies ,Aged, 80 and over ,Lymphoid Neoplasia ,SARS-CoV-2 ,business.industry ,COVID-19 ,Disease Management ,Cell Biology ,Hematology ,Middle Aged ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,United States ,Survival Rate ,Drug Therapy, Combination ,Female ,business ,Follow-Up Studies - Published
- 2021
158. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper
- Author
-
Toby A. Eyre, John Riches, Peter Hillmen, George A Follows, Piers E.M. Patten, Renata Walewska, Helen Marr, and Anna Schuh
- Subjects
Male ,medicine.medical_specialty ,Hematology ,Lymphocytic leukaemia ,Richter transformation ,business.industry ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Dermatology ,England ,Internal medicine ,medicine ,Humans ,Female ,business ,Good practice - Published
- 2021
159. Selected Body Composition Parameters Analysis Based on Bioelectrical Impedance in Patients Operated for Gastrointestinal Cancer
- Author
-
LUCYNA SCISLO, ELZBIETA WALEWSKA, IWONA BODYS-CUPAK, URSZULA SKORUS-ZADECKA, PIOTR RICHTER, and ANTONI M. SZCZEPANIK
- Subjects
Pharmacology ,Cancer Research ,Electric Impedance ,Body Composition ,Humans ,Muscle, Skeletal ,General Biochemistry, Genetics and Molecular Biology ,Research Article ,Body Mass Index ,Gastrointestinal Neoplasms - Abstract
Background/Aim: Bioelectrical Impedance Analysis is a method that evaluates body composition, useful in assessing the nutritional status of cancer patients. The analysis of its indicators may be helpful in predicting clinical course. The aim of the study was to evaluate the following body composition parameters: fat mass (FM), fat-free mass (FFM), skeletal muscle mass (SMM), muscle mass index (MMI), visceral fat (VF) and body mass index (BMI) measured before and after surgery in patients with gastrointestinal cancer and to determine the relationship between body composition and the course of treatment. Patients and Methods: The study included 125 patients, aged 65-68, operated on due to gastric, pancreatic or colorectal cancer. Body composition was assessed with electrical bioimpedance before and on the fifth postoperative day. The severity of complications was assessed with the Clavien-Dindo classification. Results: In the whole group of patients, the percentage of FM, VF, and BMI levels measured before surgery were significantly higher in curative surgery patients in comparison to palliative surgery patients, p
- Published
- 2022
160. High Dose Intravenous Fish Oil Reduces Inflammation—A Retrospective Tale from Two Centers
- Author
-
Stanislaw Klek, Dorota Mankowska-Wierzbicka, Lucyna Scislo, Elzbieta Walewska, Magdalena Pietka, and Kinga Szczepanek
- Subjects
lipid emulsions ,fish oil ,omega-3 PUFA ,omega-3 fatty acids ,parenteral nutrition ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Aim: Patients on parenteral nutrition (PN) are prone to inflammation. This may aggravate an existing proinflammatory state and become a critical factor in the development of liver dysfunction (LD). Intravenous fish oil may attenuate this inflammatory state, but data on its use in adults are scarce. The aim of this study was to investigate the effects of adding a pure fish oil intravenous lipid emulsion (ILE) into short- and long-term PN in patients either at risk of, or with existing, inflammation. Methods: A retrospective analysis of 61 patients (32 female, 29 male, mean age 51.5 ± 12.6 years) who received all-in-one PN, including amino acids, glucose, and lipids supplemented with pure fish oil ILE, was performed. Pure fish oil ILE (Omegaven®, Fresenius Kabi, Bad Homburg, Germany) was used along with the standard ILE to reach a fish oil dose of 0.4–0.5 g fish oil/kg/d. Diagnoses were chronic intestinal failure (CIF, n = 20), Crohn’s disease (CD, n = 22), and ulcerative colitis (UC, n = 19). The observation period was 12 months for CIF and 21 days for UC and CD. Results: A reduction in inflammation was noticeable in all patients and became statistically significant in CD (hsCRP p < 0.0001, ESR p = 0.0034, procalcitonin p = 0.0014, Il-6 p = 0.001) and UC groups (hsCRP and ESR p < 0.0001, Il-6 p = 0.0001, TNF-α p = 0.0113). In the CIF group, the total bilirubin concentration (p = 0.2157) and aspartate transaminase SGOT (p = 0.1785) did not vary over time. Conclusions: PN with pure fish oil ILE reduces some inflammatory parameters in IBD and maintains liver function parameters in CIF patients. Fish oil might become a valuable ingredient in both short- and long-term PN in patients at risk of liver dysfunction.
- Published
- 2020
- Full Text
- View/download PDF
161. 1,2- and 1,1-Migratory Insertion Reactions of Silylated Germylene Adducts
- Author
-
Małgorzata Walewska, Judith Baumgartner, and Christoph Marschner
- Subjects
germylene ,germanium dichloride ,1,1-insertion ,1,2-insertion ,Organic chemistry ,QD241-441 - Abstract
The reactions of the PMe3 adduct of the silylated germylene [(Me3Si)3Si]2Ge: with GeCl2·dioxane were found to yield 1,1-migratory insertion products of GeCl2 into one or two Ge−Si bonds. In a related reaction, a germylene was inserted with tris(trimethylsilyl)silyl and vinyl substituents into a Ge−Cl bond of GeCl2. This was followed by intramolecular trimethylsilyl chloride elimination to another cyclic germylene PMe3 adduct. The reaction of the GeCl2 mono-insertion product (Me3Si)3SiGe:GeCl2Si(SiMe3)3 with Me3SiC≡CH gave a mixture of alkyne mono- and diinsertion products. While the reaction of a divinylgermylene with GeCl2·dioxane only results in the exchange of the dioxane of GeCl2 against the divinylgermylene as base, the reaction of [(Me3Si)3Si]2Ge: with one GeCl2·dioxane and three phenylacetylenes gives a trivinylated germane with a chlorogermylene attached to one of the vinyl units.
- Published
- 2020
- Full Text
- View/download PDF
162. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
- Author
-
Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd, Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L. M., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., Woyach, J. A., Ferrant, E., Wierda, W. G., Munugalavadla, V., Yu, T., Wang, M. H., and Byrd, J. C.
- Subjects
Cancer Research ,Oncology ,Hematology - Abstract
ispartof: LEUKEMIA vol:36 issue:4 pages:1171-1175 ispartof: location:England status: published
- Published
- 2022
163. Management of cardiovascular complications of bruton tyrosine kinase inhibitors
- Author
-
Renata Walewska, Nilima Parry-Jones, Sunil Iyengar, Anna Schuh, Alexander R. Lyon, Terry McCormack, Piers E.M. Patten, Peter Hillmen, Gregory Y.H. Lip, Nicolas Martinez-Calle, and Chloe Pek Sang Tang
- Subjects
medicine.medical_specialty ,hypertension ,Cardiovascular Complication ,Clinical Decision-Making ,Cardiovascular System ,sudden cardiac death ,Sudden cardiac death ,Diagnosis, Differential ,chemistry.chemical_compound ,Risk Factors ,bruton tyrosine kinase inhibitor ,ibrutinib ,Internal medicine ,Agammaglobulinaemia Tyrosine Kinase ,medicine ,Animals ,Humans ,Bruton's tyrosine kinase ,atrial fibrillation ,Protein Kinase Inhibitors ,cardiovascular complication ,biology ,business.industry ,Disease Management ,Atrial fibrillation ,Hematology ,medicine.disease ,chemistry ,Cardiovascular Diseases ,Ibrutinib ,biology.protein ,Cardiology ,Disease Susceptibility ,business - Published
- 2021
164. Evidence-Based Care Reduces Unnecessary Medical Procedures and Healthcare Costs in the Outpatient Setting
- Author
-
Krzysztof Wojtkowski, Piotr Soszyński, Bożena Walewska-Zielecka, and Urszula Religioni
- Subjects
medicine.medical_specialty ,Evidence-Based Medicine ,business.industry ,Health Policy ,Economics, Econometrics and Finance (miscellaneous) ,Health Care Costs ,Evidence-based medicine ,Patient satisfaction ,Patient Satisfaction ,Intervention (counseling) ,Outpatients ,Health care ,Unnecessary Procedure ,Emergency medicine ,medicine ,Outpatient setting ,Humans ,Outpatient clinic ,Medical diagnosis ,business ,Referral and Consultation ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) - Abstract
Objectives The study aimed to examine the number of unnecessary medical procedures and healthcare costs with the use of the educational intervention in Poland. Methods Secondary data were collected between 2014 and 2015. Analysis of events and cost per patient revealed significant variability and overutilization of diagnostics and other services by physicians practicing in a network of private outpatient clinics in Poland. To reduce unjustified referrals and costs, a 2-year educational intervention was carried out, which included printed evidence-based practice recommendations and quarterly verification of the results from each of the 617 participating physicians. We analyzed the effects of the intervention on the number of medical events and costs with 17 diagnoses generating the highest costs. Results After 2 years of the intervention, the number of medical events per patient decreased by over 20% compared to baseline, primarily in orthopedics (by 31%-37%). Moreover, the healthcare costs per patient decreased by about 18% at the end of the intervention. Patient satisfaction remained high during the intervention. Conclusions Intervention based on evidence-based practice reduced both the number of unnecessary medical procedures and healthcare costs in the outpatient setting, while not affecting patient satisfaction.
- Published
- 2021
165. Occurrence of male depression symptoms, suicidal behaviors, alcohol and tobacco use and level of personal resources in three male groups
- Author
-
Anna Mosiołek, Mariusz Jaworski, Aleksandra Kielan, Bożena Walewska-Zielecka, Jan Chodkiewicz, and Łukasz Święcicki
- Subjects
medicine.medical_specialty ,Medicine (General) ,Tobacco use ,business.industry ,Addiction ,media_common.quotation_subject ,Alcohol ,Test (assessment) ,Nicotine ,substance-related disorders ,chemistry.chemical_compound ,R5-920 ,chemistry ,Medicine ,suicide behaviors ,Psychological resilience ,personal resources ,business ,Psychiatry ,Physical disorder ,Depression (differential diagnoses) ,media_common ,medicine.drug ,male depression symptoms - Abstract
Background and objective: The study was to compare the severity of male depression symptoms, suicidal behaviors, the use of psychoactive substances (alcohol, nicotine), and evaluate personal resources (self-efficacy, coping strategies and resilience) among men from three different groups. Material and methods: The clinical group contained men with depression disorders diagnosed by psychiatrists and treated in psychiatric hospitals (n = 197). The control groups contained men with physical disorders treated in general hospitals in Warsaw, Poland (n = 198) and men who self-evaluated themselves as healthy without physical or mental disorders (n = 203). Several tests were used for evaluation: a test with sociodemographic variables, the AUDIT Test, the Fagerstrom Test, the Generalized Self-Efficacy Scale (GSES), the MINI-COPE Questionnaire, the Resilience Evaluation Questionnaire (KOP-26), the Suicide Behaviors Questionnaire-Revised by Osman (SBQ-R) and the Gotland Male Depression Scale (GMDS). Results: Most of the men with depression disorders presented non-typical symptoms of depression which are not included in diagnostic criteria. It allows us to assume that a large percentage of men who suffer from depression are not properly being diagnosed. Moreover, we found that men with any type of physical disorder have the greatest severity of male depression symptoms than healthy men. Men with depression disorders have suicidal thoughts and have made efforts in the past more often, as well as having higher alcohol and nicotine addictions. Patients who overuse or are addicted to alcohol or nicotine should be additionally screened for the possible occurrence of depressive disorders, and substance usage should be treated as a symptom of male depression. Men with depression present low resilience and low self-efficacy. They also use negative strategies in dealing with stress. Conclusion: There is a need to plan and implement effective prevention actions that will take the conditioning of these groups into account.
- Published
- 2021
166. Computerized neuropsychological assessment of executive functions: a scoping review
- Author
-
Zukoski, Walewska and Hamdan, Amer
- Subjects
FOS: Psychology ,Computerized neuropsychological assessment ,Executive Function ,Cognitive Psychology ,Psychology ,Social and Behavioral Sciences - Abstract
The objective of the study is to analyze the scientific literature in which computerized instruments are being tested or developed for neuropsychological assessment of executive functions.
- Published
- 2022
- Full Text
- View/download PDF
167. Blood Pressure Changes During Mechanical Thrombectomy for Acute Ischemic Stroke Are Associated With Serious Early Treatment Complications: Symptomatic Intracerebral Hemorrhage and Malignant Brain Edema
- Author
-
Wiącek, Marcin, primary, Szymański, Maciej, additional, Walewska, Klaudia, additional, and Bartosik-Psujek, Halina, additional
- Published
- 2022
- Full Text
- View/download PDF
168. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study
- Author
-
Berak, Hanna, Laskus, Tomasz, Kołakowska-Rządzka, Anna, Wasilewski, Marek, Stańczak, Janusz J., Bardadin, Krzysztof, Walewska-Zielecka, Bożena, and Horban, Andrzej
- Published
- 2014
- Full Text
- View/download PDF
169. A disulfide tether stabilizes the block of sodium channels by the conotoxin μO§-GVIIJ
- Author
-
Gajewiak, Joanna, Azam, Layla, Imperial, Julita, Walewska, Aleksandra, Green, Brad R., Bandyopadhyay, Pradip K., Raghuraman, Shrinivasan, Ueberheide, Beatrix, Bern, Marshall, Zhou, H. Mimi, Minassian, Natali A., Hagan, Rebecca H., Flinspach, Mack, Yi Liu, Bulaj, Grzegorz, Wickenden, Alan D., Olivera, Baldomero M., Yoshikami, Doju, and Zhang, Min-Min
- Published
- 2014
170. Efficacy of the use of unsaponifiable fractions of avocado and soybean oil in osteoarthritis
- Author
-
Ewa Walewska
- Subjects
food.ingredient ,food ,Unsaponifiable ,Chemistry ,medicine ,General Medicine ,Osteoarthritis ,Food science ,medicine.disease ,Soybean oil - Abstract
Osteoarthritis, which affects approximately 18% of women and 10% of men after the age of 60, is undoubtedly a serious public problem. The main pathological changes in osteoarthritis include the degeneration and loss of articular cartilage, changes in the subchondral bone and osteophyte formation in the bone epiphyses. Pain accompanying degenerative modifications significantly reduces the quality of life of patients. The purpose of this article is to discuss the use of unsaponifiable fractions of avocado and soybean oil to control the symptoms of osteoarthritis of the knee on a case-by-case basis.
- Published
- 2021
171. Independent verification of treatment planning system calculations
- Author
-
Edyta Dąbrowska-Szewczyk, Anna Zawadzka, Beata Brzozowska, Agnieszka Walewska, and Paweł Kukołowicz
- Subjects
03 medical and health sciences ,Nuclear and High Energy Physics ,0302 clinical medicine ,Nuclear Energy and Engineering ,Computer science ,030220 oncology & carcinogenesis ,Condensed Matter Physics ,Safety, Risk, Reliability and Quality ,Radiation treatment planning ,Waste Management and Disposal ,Instrumentation ,030218 nuclear medicine & medical imaging ,Reliability engineering - Abstract
Purpose According to the available international recommendations, at least one independent verification of the calculations of number of monitor unit (MU) is required for every patient treated by teleradiotherapy. The aim of this study was to estimate the differences of dose distributions calculated with two treatment planning systems: Eclipse (Varian) and Oncentra MasterPlan (Elekta). Materials and methods The analysis was performed for 280 three-dimensional conformal radiotherapy treatment (3D-CRT) plans with photon beams from Varian accelerators: CL 600C/D X6 MV (109 plans), CL 2300C/D X6 MV (43 plans), and CL 2300C/D X15 MV (128 plans). The mean doses in the planning target volume (PTV) and doses at the isocenter point obtained with Eclipse and Oncentra MasterPlan (OMP) were compared with Wilcoxon matched-pairs signed rank test. Additionally, the treatment planning system (TPS) calculations were compared with dosimetric measurements performed in the inhomogeneous phantom. Results Data were analysed for 6 MV plans and for 15 MV plans separately, independently of the treatment machine. The dose values calculated in Eclipse were significantly (p Conclusions OMP calculations were introduced as the independent MU verification tool with the first action level range equal to 3.5%.
- Published
- 2021
172. From hospital unit to intestinal failure center: Twenty years of history
- Author
-
Stanislaw Klek, Justyna Zamarska, M. Kupiec, M. Pietka, Lucyna Scislo, M. Sumlet, Eliza Kowalczyk, Kinga Szczepanek, and Elżbieta Walewska
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Patients ,Fistula ,030209 endocrinology & metabolism ,Critical Care and Intensive Care Medicine ,History, 21st Century ,Hospitals, Special ,Intestinal Failure ,03 medical and health sciences ,0302 clinical medicine ,Intestinal failure ,medicine ,Humans ,Reimbursement ,Retrospective Studies ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,Medical record ,General surgery ,History, 20th Century ,medicine.disease ,Short bowel syndrome ,Catheter ,Parenteral nutrition ,Mesenteric ischemia ,Poland ,Parenteral Nutrition, Home ,business ,Delivery of Health Care - Abstract
Summary Aim Home parenteral nutrition (HPN) is one of the most demanding medical therapies as it is the only option for patients for intestinal failure (IF). No unequivocal policy on how to start and progress with HPN has ever been presented. The IF Center at the Stanley Dudrick's Memorial Hospital in Skawina is one of the biggest centers in Poland, celebrating its twentieth birthday last year. It offered the unique chance to present how to create and grow the IF center, increasing the quality of care. The above became the aim of this study. Methods A retrospective analysis of all medical records of HPN patients from the University Hospital and Stanley Dudrick's Memorial Hospital in Skawina. Patient profile, clinical course and treatment outcomes were assessed. The evolution of all aspects of HPN is presented. A brief historical perspective has been added to better illustrate the center's growth and transformation. Results 608 patients (363 female, 245 male, mean age 55.55 year) from all over Poland were treated between December 1999 and December 2019. The most frequent indication for HPN was mechanical obstruction (277, 45.7%), followed by short bowel syndrome (SBS, 208, 34.3%) and intestinal fistula (46, 7.59%). The most common primary disease was cancer (n = 267), followed by mesenteric ischemia (n = 104), and surgical complications (n = 62). 314 patients (51.8%) died. 73 (12.04%) were successfully weaned off PN. The catheter infection rate reached 0.39/1000 catheter days. Conclusions the founding of the HPN center and its further development is possible provided that there is team of dedicated people, supported by hospital base. The real growth opportunity is guaranteed by the reimbursement. It is necessary to adapt to the changing circumstances.
- Published
- 2021
173. The Genomic and Epigenomic Landscape of Chronic Lymphocytic Leukemia
- Author
-
Strefford, Jonathan C., primary, Walewska, Renata, additional, and Oscier, David G., additional
- Published
- 2017
- Full Text
- View/download PDF
174. A short proof that equisingular plane curve singularities are topologically equivalent
- Author
-
Brzostowski, Szymon, primary, Krasiński, Tadeusz, additional, and Walewska, Justyna, additional
- Published
- 2017
- Full Text
- View/download PDF
175. Clinical Applicability of Whole-Exome Sequencing Exemplified by a Study in Young Adults with the Advanced Cryptogenic Cholestatic Liver Diseases
- Author
-
Maria Kulecka, Andrzej Habior, Agnieszka Paziewska, Krzysztof Goryca, Michalina Dąbrowska, Filip Ambrozkiewicz, Bożena Walewska-Zielecka, Andrzej Gabriel, Michal Mikula, and Jerzy Ostrowski
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background. The proper use of new medical tests in clinical practice requires the establishment of their value and range of diagnostic usefulness. While whole-exome sequencing (WES) has already entered the medical practice, recognizing its diagnostic usefulness in multifactorial diseases has not yet been achieved. Aims. The objective of this study was to establish usability of WES in determining genetic background of chronic cholestatic liver disease (CLD) in young patients. Methods. WES was performed on six young patients (between 17 and 22 years old) with advanced fibrosis or cirrhosis due to CLD and their immediate families. Sequencing was performed on an Ion Proton sequencer. Results. On average, 19,673 variants were identified, of which from 7 to 14 variants of an individual were nonsynonymous, homozygous, recessively inherited, and considered in silico as pathogenic. Although monogenic cause of CLD has not been determined, several heterozygous rare variants and polymorphisms were uncovered in genes previously known to be associated with CLD, including ATP8B1, ABCB11, RXRA, and ABCC4, indicative of multifactorial genetic background. Conclusions. WES is a potentially useful diagnostic tool in determining genetic background of multifactorial diseases, but its main limitation results from the lack of opportunities for direct linkage between the uncovered genetic variants and molecular mechanisms of disease.
- Published
- 2017
- Full Text
- View/download PDF
176. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1
- Author
-
Larrayoz, M, Blakemore, S J, Dobson, R C, Blunt, M D, Rose-Zerilli, M J J, Walewska, R, Duncombe, A, Oscier, D, Koide, K, Forconi, F, Packham, G, Yoshida, M, Cragg, M S, Strefford, J C, and Steele, A J
- Published
- 2016
- Full Text
- View/download PDF
177. Impacts of a Re-designed Care Path for Back Pain Directing Patients to Physiotherapists
- Author
-
Agnieszka Motyl, Małgorzata Kiljańska, Piotr Soszyński, and Bożena Walewska-Zielecka
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Primary care ,Patient Care Planning ,Post-intervention ,Net Promoter ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,health services administration ,Health care ,Back pain ,medicine ,Humans ,health care economics and organizations ,Rehabilitation ,business.industry ,Public Health, Environmental and Occupational Health ,030210 environmental & occupational health ,Intervention studies ,Physical Therapists ,Back Pain ,Physical therapy ,Sick Leave ,medicine.symptom ,business ,Low Back Pain - Abstract
OBJECTIVE To evaluate impact of directing patients with back pain for first visit to a physiotherapist on sick leaves, healthcare utilization, and patient satisfaction. METHODS Pre-post intervention study of 70,138 patients treated in Poland for back pain: 27,034 before the care pathway redesign and 43,104 after. RESULTS After the redesign, all per-patient measures (mean ± SD) significantly decreased over the 12-month follow-up: sick leaves number from 0.32 ± 0.87 to 0.29 ± 0.86, sick leaves days from 2.78 ± 11.56 to 2.56 ± 11.25, doctors' visits from 2.02 ± 1.70 to 1.51 ± 1.63, diagnostic imaging services from 0.63 ± 0.79 to 0.43 ± 0.71 and rehabilitation services from 7.55 ± 14.90 to 4.70 ± 12.61.The Net Promoter Score was higher for physiotherapist (83), than for orthopedists (59), primary care (74), or neurologists (67). CONCLUSIONS Involving physiotherapists early in the back pain care may result in benefits for patients and healthcare organizations.
- Published
- 2021
178. Albumin and total protein concentration – selected parameters of catabolic reaction and nutritional status among patients with craniocerebral injuries diagnosed with surgically treated cerebrovascular diseases
- Author
-
Stanisław Wojtan, Magdalena Staszkiewicz, Elżbieta Walewska, Lucyna Ścisło, Małgorzata Paplaczyk, and Maria Kózka
- Subjects
business.industry ,Catabolism ,Albumin ,Physiology ,catabolism ,Nutritional status ,nrs 2002 ,General Medicine ,total protein ,nutritional status ,Medicine ,business ,albumin ,Total protein - Published
- 2021
179. (2-Aminoaryl)iminophosphoranes as Versatile Starting Materials for the Synthesis of 1-Aryl-2-trifluoromethylbenzimidazoles
- Author
-
Wróbel, Zbigniew, primary, Walewska-Królikiewicz, Magdalena, additional, Wilk, Bogdan, additional, and Kwast, Andrzej, additional
- Published
- 2022
- Full Text
- View/download PDF
180. P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
- Author
-
Sharman, J. P., primary, Egyed, M., additional, Jurczak, W., additional, Skarbnik, A., additional, Patel, K., additional, Flinn, I. W., additional, Kamdar, M., additional, Munir, T., additional, Walewska, R., additional, Fogliatto, L. M., additional, Herishanu, Y., additional, Banerji, V., additional, Follows, G., additional, Walker, P., additional, Karlsson, K., additional, Ghia, P., additional, Janssens, A., additional, Cymbalista, F., additional, Ferrant, E., additional, Wierda, W. G., additional, Munugalavadla, V., additional, Yu, T., additional, Wang, M. H., additional, and Woyach, J. A., additional
- Published
- 2022
- Full Text
- View/download PDF
181. P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS
- Author
-
Nadeu, F., primary, Shuai, S., additional, Clot, G., additional, Hilton, L. K., additional, Diaz-Navarro, A., additional, Martín, S., additional, Royo, R., additional, Baumann, T., additional, Kulis, M., additional, López-Oreja, I., additional, Cossio, M., additional, Lu, J., additional, Ljungström, V., additional, Young, E., additional, Plevova, K., additional, Knisbacher, B. A., additional, Lin, Z., additional, Hahn, C. K., additional, Bousquets, P., additional, Alcoceba, M., additional, González, M., additional, Colado, E., additional, Aymerich, M., additional, Terol, M. J., additional, Rivas-Delgado, A., additional, Enjuanes, A., additional, Ruiz-Gaspà, S., additional, Chatzikonstantinou, T., additional, Hägerstrand, D., additional, Jylhä, C., additional, Skaftason, A., additional, Mansouri, L., additional, Stranska, K., additional, Doubek, M., additional, van Gastel-Mol, E. J., additional, Davis, Z., additional, Walewska, R., additional, Scarfò, L., additional, Trentin, L., additional, Visentin, A., additional, Parikh, S. A., additional, Rabe, K. G., additional, Moia, R., additional, Armand, M., additional, Rossi, D., additional, Davi, F., additional, Gaidano, G., additional, Kay, N. E., additional, Shanafelt, T., additional, Ghia, P., additional, Oscier, D., additional, Langerak, A. W., additional, Beà, S., additional, López-Guillermo, A., additional, Neuberg, D., additional, Wu, C. J., additional, Getz, G., additional, Pospisilova, S., additional, Stamatopoulos, K., additional, Rosenquist, R., additional, Huber, W., additional, Zenz, T., additional, Colomer, D., additional, Martín-Subero, J. I., additional, Delgado, J., additional, Morin, R. D., additional, Stein, L. D., additional, Puente, X. S., additional, and Campo, E., additional
- Published
- 2022
- Full Text
- View/download PDF
182. Expanding chemical diversity of conotoxins: Peptoid–peptide chimeras of the sodium channel blocker μ-KIIIA and its selenopeptide analogues
- Author
-
Walewska, Aleksandra, Han, Tiffany S., Zhang, Min-Min, Yoshikami, Doju, Bulaj, Grzegorz, and Rolka, Krzysztof
- Published
- 2013
- Full Text
- View/download PDF
183. Gas Signaling Molecules and Mitochondrial Potassium Channels
- Author
-
Agnieszka Walewska, Adam Szewczyk, and Piotr Koprowski
- Subjects
mitochondria ,potassium channels ,KATP channel ,BKCa channel ,gasotransmitters ,carbon monoxide ,nitric oxide ,hydrogen sulfide ,heme ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Recently, gaseous signaling molecules, such as carbon monoxide (CO), nitric oxide (NO), and hydrogen sulfide (H2S), which were previously considered to be highly toxic, have been of increasing interest due to their beneficial effects at low concentrations. These so-called gasotransmitters affect many cellular processes, such as apoptosis, proliferation, cytoprotection, oxygen sensing, ATP synthesis, and cellular respiration. It is thought that mitochondria, specifically their respiratory complexes, constitute an important target for these gases. On the other hand, increasing evidence of a cytoprotective role for mitochondrial potassium channels provides motivation for the analysis of the role of gasotransmitters in the regulation of channel function. A number of potassium channels have been shown to exhibit activity within the inner mitochondrial membrane, including ATP-sensitive potassium channels, Ca2+-activated potassium channels, voltage-gated Kv potassium channels, and TWIK-related acid-sensitive K+ channel 3 (TASK-3). The effects of these channels include the regulation of mitochondrial respiration and membrane potential. Additionally, they may modulate the synthesis of reactive oxygen species within mitochondria. The opening of mitochondrial potassium channels is believed to induce cytoprotection, while channel inhibition may facilitate cell death. The molecular mechanisms underlying the action of gasotransmitters are complex. In this review, we focus on the molecular mechanisms underlying the action of H2S, NO, and CO on potassium channels present within mitochondria.
- Published
- 2018
- Full Text
- View/download PDF
184. Patient age, refractive index of the corneal stroma, and outcomes of uneventful laser in situ keratomileusis
- Author
-
Patel, Sudi, Alió, Jorge L., Walewska, Anna, Amparo, Francisco, and Artola, Alberto
- Published
- 2013
- Full Text
- View/download PDF
185. Examples of mental health campaigns targeted at men
- Author
-
Bożena Walewska-Zielecka, Polskie Towarzystwo Suicydologiczne, Warszawa, Polska, Uniwersytet Marii Curie-Skłodowskiej w Lublinie, Lublin, Polska, Marlena Stradomska, and Aleksandra Kielan
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,medicine.medical_specialty ,medicine ,Psychology ,Psychiatry ,Mental health - Abstract
Men commit suicide more frequently than women in nearly all parts of the world. This is due to a number of factors, including the fact that women tend to seek mental help relatively more often than men. Many developed countries have attempted to implement suicide prevention programmes and initiatives, but only a small proportion of these have targeted men directly. The aims of this paper are to highlight preventive measures focusing on mental problems experienced specifically by men, and provide a detailed description of these measures. Consequently, the paper has both theoretical and practical dimensions, outlining the challenges and presenting potential solutions. The study discusses selected examples of mental health actions targeting men which were carried out in several countries around the world including Japan (“Daddy, have you slept well?”), UK (“Heads Up” campaign), United States (“Real men. Real depression”), Canada (“HeadsUpGuys” campaign), and Australia (Movember), as well as social media campaigns (Instagram: #HereForYou). Men are often reluctant to reveal their mental problems (stress, low mood, insomnia, suicidal ideation), which can be attributed to the so-called macho culture existing in societies. The man is traditionally considered head of the family, a guardian and leader, a strong personality, and a person to rely on. This perception contributes to the fact that men tend not to admit their weaknesses in front of family or friends. It is recommended that preventive actions take into account such aspects as the transfer of knowledge, skills and competences in the areas of identification of mental problems, and abilities to cope with a crisis situation. Mental health actions should be launched in areas frequently visited by men including workplaces, buses, pubs, bars, sports clubs, stadiums or other meeting places, so that the information can reach the largest possible target group.
- Published
- 2020
186. Suicide and mental health problems in men in Poland
- Author
-
Bożena Walewska-Zielecka, Anna Mosiołek, Neurology, Warsaw, Poland, Jan Chodkiewicz, Mariusz Jawoski, Aleksandra Kielan, Marlena Stradomska, and Łukasz Święcicki
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,medicine.medical_specialty ,medicine ,Psychiatry ,Psychology ,Mental health - Abstract
Background: Women in Poland suffer from mental disorders more often than men (except for addictions). However, men are about six times more likely to commit suicide than women. What could be the cause of this situation? The aim of the article was to analyse the potential correlation between mental health and suicide in men. Materials and methods: The review was based on the available scientific literature on male depression and suicide. We searched Pubmed, Scopus and Google Schoolar (from 1.11.2019 to 31.01.2020). Results: Polish statistics may differ from others due to the fact that current diagnostic criteria often fail to take into consideration the typical symptoms of mental disorders in men. Male suicide attempts are more commonly lethal. Men are also more likely to try to deal with mental problems on their own, often using alcohol, which, in many cases, leads to suicidal behaviour and addictions. This disparity between the numbers of suicides among men and women in recent years indicates an urgent need to promote mental health among men. Conclusions: Polish health policies should focus more on the mental health of men. It is very important to develop standards of promoting male mental health, which would meet the specific health needs of this group. It is necessary to provide physicians with new diagnostic tools which will allow for better identification of typical male symptoms of mental disorders.
- Published
- 2020
187. Worldwide Examination of Patients with CLL Hospitalized for COVID-19
- Author
-
Lindsey E Roeker, Lydia Scarfo, Thomas Chatzikonstantinou, Pau Abrisqueta, Toby A. Eyre, Raul Cordoba, Ana Muntañola Prat, Guillermo Villacampa, Lori A. Leslie, Michael Koropsak, Giulia Quaresmini, John N. Allan, Richard R. Furman, Erica B Bhavsar, John M. Pagel, Jose Angel Hernandez-Rivas, Krish Patel, Marina Motta, Neil Bailey, Fatima Miras, Nicole Lamanna, Rosalia Alonso, Santiago Osorio-Prendes, Candida Vitale, Manali Kamdar, Patricia Baltasar, Anders Österborg, Lotta Hanson, Mónica Baile, Ines Rodríguez-Hernández, Susana Valenciano, Viola Maria Popov, Abelardo Barez Garcia, Ana Alfayate, Ana C Oliveira, Barbara Eichhorst, Francesca M. Quaglia, Gianluigi Reda, Javier Lopez Jimenez, Marzia Varettoni, Monia Marchetti, Pilar Romero, Rosalía Riaza Grau, Talha Munir, Amaya Zabalza, Ann Janssens, Carsten U Niemann, Guilherme Fleury Perini, Julio Delgado, Lucrecia Yanez San Segundo, Ma Isabel Gómez Roncero, Matthew Wilson, Piers Patten, Roberto Marasca, Sunil Iyengar, Amanda Seddon, Ana Torres, Angela Ferrari, Carolina Cuéllar-García, Daniel Wojenski, Dima El-Sharkawi, Gilad Itchaki, Helen Parry, Juan José Mateos-Mazón, Nicolas Martinez-Calle, Shuo Ma, Daniel Naya, Ellen Van Der Spek, Erlene K. Seymour, Eva Gimeno Vázquez, Gian Matteo Rigolin, Francesca Romana Mauro, Harriet S Walter, Jorge Labrador, Lorenzo De Paoli, Luca Laurenti, Elena Ruiz, Mark-David Levin, Martin Šimkovič, Martin Špaček, Rafa Andreu, Renata Walewska, Sonia Perez-Gonzalez, Suchitra Sundaram, Adrian Wiestner, Amalia Cuesta, Angus Broom, Arnon P. Kater, Begoña Muiña, César A Velasquez, Chaitra S. Ujjani, Cristina Seri, Darko Antic, Dominique Bron, Elisabeth Vandenberghe, Elise A. Chong, Enrico Lista, Fiz Campoy García, Giovanni Del Poeta, Inhye Ahn, Jeffrey J. Pu, Jennifer R Brown, Juan Alfonso Soler Campos, Lara Malerba, Livio Trentin, Lorella Orsucci, Lucia Farina, Lucia Villalon, Maria Jesus Vidal, Maria Jose Sanchez, Maria Jose Terol, Maria Rosaria De Paolis, Massimo Gentile, Matthew S. Davids, Mazyar Shadman, Mohamed A Yassin, Myriam Foglietta, Ozren Jaksic, Paolo Sportoletti, Paul M. Barr, Rafael Ramos, Raquel Santiago, Rosa Ruchlemer, Sabina Kersting, Scott F. Huntington, Tobias Herold, Yair Herishanu, Meghan C. Thompson, Sonia Lebowitz, Christine Ryan, Ryan W. Jacobs, Craig A. Portell, Krista Isaac, Alessandro Rambaldi, Chadi Nabhan, Danielle M. Brander, Emili Montserrat, Giuseppe Rossi, Jose A. Garcia-Marco, Marta Coscia, Nikita Malakhov, Noemi Fernandez-Escalada, Sigrid Strand Skånland, Callie C. Coombs, Paola Ghione, Stephen J. Schuster, Robin Foà, Antonio Cuneo, Francesc Bosch, Kostas Stamatopoulos, Paolo Ghia, Anthony R. Mato, and Meera Patel
- Subjects
education.field_of_study ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Venetoclax ,902.Health Services Research-Malignant Conditions (Lymphoid Disease) ,Immunology ,Population ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Chemoimmunotherapy ,Internal medicine ,Case fatality rate ,Cohort ,Clinical endpoint ,Medicine ,Lymphocytopenia ,education ,business - Abstract
Introduction: Patients (pts) with CLL may be at particular risk of severe COVID-19 given advanced age and immune dysregulation. Two large series with limited follow-up have reported outcomes for pts with CLL and COVID-19 (Scarfò, et al. Leukemia 2020; Mato, et al. Blood 2020). To provide maximal clarity on outcomes for pts with CLL and COVID-19, we partnered in a worldwide effort to describe the clinical experience and validate predictors of survival, including potential treatment effects. Methods: This international collaboration represents a partnership between investigators at 141 centers. Data are presented in two cohorts. Cohort 1 (Co1) includes pts captured through efforts by European Research Initiative on CLL (ERIC), Italian CAMPUS CLL Program, and Grupo Español de Leucemia Linfática Crónica. The validation cohort, Cohort 2 (Co2), includes pts from US (66%), UK (23%), EU (7%), and other countries (4%). There is no overlap in cases between cohorts. CLL pts were included if COVID-19 was diagnosed by PCR detection of SARS-CoV-2 and they required inpatient hospitalization. Data were collected retrospectively 2/2020 - 5/2020 using standardized case report forms. Baseline characteristics, preexisting comorbidities (including cumulative illness rating scale (CIRS) score ≥6 vs. The primary endpoint of this study was to estimate the case fatality rate (CFR), defined as the proportion of pts who died among all pts hospitalized with COVID-19. Chi-squared test was used to compare frequencies; univariable and multivariable analyses utilized Cox regression. Predictors of inferior OS in both Co1 and Co2 were included in multivariable analyses. Kaplan-Meier method was used to estimate overall survival (OS) from time of COVID-19 diagnosis (dx). Results: 411 hospitalized, COVID-19 positive CLL pts were analyzed (Co1 n=281, Co2 n=130). Table 1 describes baseline characteristics. At COVID-19 dx, median age was 72 in Co1 (range 37-94) and 68 in Co2 (range 41-98); 31% (Co1) and 45% (Co2) had CIRS ≥6. In Co1, 48% were treatment-naïve and 26% were receiving CLL-directed therapy at COVID-19 dx (66% BTKi ± anti-CD20, 19% Venetoclax ± anti-CD20, 9.6% chemo/chemoimmunotherapy (CIT), 1.4% PI3Ki, 4% other). In Co2, 36% were never treated and 49% were receiving CLL-directed therapy (65% BTKi ± anti-CD20, 19% Venetoclax ± anti-CD20, 9.4% multi-novel agent combinations, 1.6% CIT, 1.6% PI3Ki, 1.6% anti-CD20 monotherapy, 1.6% other). Most pts receiving CLL-directed therapy had it held at COVID-19 diagnosis (93% in Co1 and 81% in Co2). Frequency of most COVID-19 symptoms/laboratory abnormalities were similar in the two cohorts including fever (88% in both), lymphocytosis (ALC ≥30 x 109/L; 27% vs. 21%), and lymphocytopenia (ALC < 1.0 x 109/L; 18% vs. 28%), while others varied between Co1 and Co2 (p Median follow-up was 24 days (range 2-86) in Co1 and 17 days (1-43) in Co2. CFRs were similar in Co1 and Co2, 30% and 34% (p=0.45). 54% and 43% were discharged while 16% and 23% remained admitted at last follow-up in Co1 and Co2, respectively. The proportion of pts requiring supplemental oxygen was similar (89% vs. 92%) while rate of ICU admission was higher in Co2 (20% vs. 48%, p Conclusions : In the largest cancer dx-specific cohort reported, pts with CLL hospitalized for COVID-19 had a CFR of 30-34%. Advanced patient age at COVID-19 diagnosis was an independent predictor of OS in two large cohorts. This CFR will serve as a benchmark for mortality for future outcomes studies, including therapeutic interventions for COVID-19 in this population. The effect of CLL treatment on OS was inconsistent across cohorts; COVID-19 may be severe regardless of treatment status. While there were no significant differences in distribution of current lines of therapy between cohorts, prior chemo exposure was more common in Co1 vs. Co2, which may account for difference in OS. Extended follow-up will be presented. Disclosures Roeker: American Society of Hematology: Research Funding; Abbott Laboratories: Other: spouse with minority ownership interest ; AbbVie: Other: spouse with minority ownership interest . Scarfo:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees. Abrisqueta:Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau. Eyre:AbbVie: Consultancy, Honoraria, Other: travel support; Gilead: Consultancy, Honoraria, Other: travel support; Janssen: Consultancy, Honoraria, Other: travel support; KITE, AZ, Loxo Oncology at Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Muntañola Prat:Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; participated in advisory boards; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; participated in advisory boards; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; participated in advisory boards. Villacampa:AstraZeneca: Other: advisory role; Merck Sharp & Dohme: Honoraria. Leslie:AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Speakers Bureau; KitePharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene/BMS: Speakers Bureau; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pharmacyclics/Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Epizyme: Speakers Bureau; Karyopharm: Speakers Bureau; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Allan:Acerta, Genentech, Abbvie, Sunesis, Ascentage, Pharmacyclics, Janssen, AstraZeneca, BeiGene: Consultancy; Celgene, Genentech, Janssen, TG Therapeutics: Research Funding; Abbvie, Janssen, AstraZeneca, Pharmacyclics: Honoraria. Furman:Incyte: Consultancy; Genentech: Consultancy; Sunesis: Consultancy; Pharmacyclics: Consultancy; Loxo Oncology: Consultancy; Oncotarget: Consultancy; Janssen: Consultancy, Speakers Bureau; TG Therapeutics: Consultancy, Research Funding; Abbvie: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy, Research Funding; Acerta: Consultancy; Verastem: Consultancy. Pagel:BeiGene, Astrazeneca, Loxo Oncology, Gilead: Consultancy. Hernandez-Rivas:Gilead: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Rovi: Membership on an entity's Board of Directors or advisory committees. Patel:Genentech: Consultancy, Speakers Bureau; Adaptive Biotechnologies: Consultancy; Janssen: Consultancy, Speakers Bureau; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy; Kite: Consultancy; Pharmacyclics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau. Motta:Roche: Honoraria; Janssen: Honoraria. Lamanna:AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Verastem: Research Funding; Bei-Gene: Research Funding; TG Therapeutics: Research Funding; Acerta: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche-Genentech: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Vitale:Janssen: Honoraria. Kamdar:Roche: Research Funding. Österborg:BeiGene: Research Funding; Kancera: Current equity holder in publicly-traded company, Research Funding; Sanofi: Consultancy; Karolinska Univeristy Hospital, Stockholm, Sweden: Current Employment. Hanson:Janssen-Cilag: Research Funding; Gilead: Research Funding; AbbVie: Honoraria. Eichhorst:ArQule: Consultancy, Honoraria, Other: travel support, Research Funding; BeiGene: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: travel support, Research Funding; Oxford Biomedica: Consultancy, Honoraria, Other: travel support, Research Funding; AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding; Novartis: Consultancy, Honoraria, Other: travel support, Research Funding. Reda:Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Varettoni:Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel/accommodations/expenses; AbbVie: Other: Travel/accommodations/expenses; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees. Marchetti:Gilead: Consultancy; Novartis: Speakers Bureau; Amgen: Speakers Bureau; AbbVie: Other: Sponsored meetings; Takeda: Other: Sponsored meetings; Pfeizer: Other: Sponsored meetings. Munir:F. Hoffmann-La Roche: Consultancy, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland; Alexion: Honoraria. Zabalza:Janssen: Honoraria, Other: travel grants; Roche: Other: travel grants; Novartis: Other: travel grants. Janssens:Amgen: Consultancy, Other: travel grants; speaker fees; Abbvie: Consultancy, Other: travel grants; speaker fees; Celgene: Consultancy, Other: travel grants; speaker fees; Janssen: Consultancy, Other: travel grants; speaker fees; Gilead: Consultancy, Other: travel grants; speaker fees; Novartis: Consultancy, Other: travel grants; speaker fees; Sanofi-Genzyme: Consultancy, Other: travel grants; speaker fees; Roche: Consultancy, Other: travel grants; speaker fees. Niemann:AstraZeneca: Honoraria, Research Funding; CSL Behring: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Sunesis: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Danish Cancer Society: Honoraria, Research Funding; Novo Nordisk Foundation: Honoraria, Research Funding. Perini:Takeda: Honoraria; Janssen: Honoraria, Speakers Bureau; Abbvie: Speakers Bureau. Patten:AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Honoraria. Marasca:Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Honoraria. Iyengar:Janssen: Honoraria; Gilead: Honoraria. Ferrari:Abbvie: Honoraria. El-Sharkawi:Roche: Other: Conference fees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Itchaki:Abbvie Inc: Consultancy, Research Funding. Ma:Novartis: Research Funding; Juno: Research Funding; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding, Speakers Bureau; Kite: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Bioverativ: Consultancy, Honoraria; BeiGene: Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding; TG Therapeutics: Research Funding. Van Der Spek:AMGEN: Other: Teaching activities. Seymour:Seattle Genetics: Research Funding; Merck: Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen/Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Genentech: Research Funding; Bristol-Myers Squibb: Research Funding. Rigolin:Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Mauro:Roche: Other; Octopharma: Other; Takeda-Shire: Other; Gilead: Other; Janssen: Other; Abbvie: Other. Laurenti:Janssen: Honoraria; Gilead: Honoraria; AbbVie: Honoraria; Roche: Honoraria. Levin:Janssen: Membership on an entity's Board of Directors or advisory committees, Other: travel compensation; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: travel compensation; Roche: Membership on an entity's Board of Directors or advisory committees, Other: travel compensation. Špaček:Gilead: Honoraria; Abbvie: Honoraria; Janssen: Honoraria. Walewska:AbbVie: Other: sponsored for educational meetings, Speakers Bureau; Janssen: Other: sponsored for educational meetings, Speakers Bureau; Gilead: Speakers Bureau; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees. Wiestner:Pharmacyclics LLC, an AbbVie Company; Acerta, Merck, Nurix, Verastem, and Genmab: Research Funding; National Institutes of Health: Patents & Royalties: and other intellectual property. Broom:Gilead: Other: Travel support, Speakers Bureau. Kater:Abbvie: Research Funding; Roche: Research Funding; Janssen: Research Funding; Celgene: Research Funding; Genentech: Research Funding. Ujjani:AstraZeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Verastem Oncology: Consultancy, Honoraria; Gilead/Kite: Consultancy, Research Funding; Atara: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; MorphoSys: Consultancy. Vandenberghe:Celgene: Other: sponsorship to attend Lugano lymphoma meeting in 2019; Gilead: Other: travel grants, Research Funding; Abbvie: Other: travel grants, Research Funding; Janssen: Other: travel grants; Roche: Other: travel grants, Research Funding. Chong:Novartis: Membership on an entity's Board of Directors or advisory committees; Tessa: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; KITE Pharma: Membership on an entity's Board of Directors or advisory committees. Pu:Takeda Pharmaceuticals: Consultancy. Brown:Janssen, Teva: Speakers Bureau; Gilead, Loxo, Sun, Verastem: Research Funding; Abbvie, Acerta, AstraZeneca, Beigene, Invectys, Juno/Celgene, Kite, Morphosys, Novartis, Octapharma, Pharmacyclics, Sunesis, TG Therapeutics, Verastem: Consultancy. Trentin:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Octapharma: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Shire: Honoraria. Farina:Abbvie: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Sanchez:Abbvie: Other: travel grants; Amgem: Other: travel grants; Janssen: Other: travel grants; Celgene: Other: travel grants; Roche: Other: travel grants. Shadman:Abbvie, Genentech, Astra Zeneca, Sound Biologics , Pharmacyclics, Verastem, ADC therapeutics, Beigene, Cellectar, BMS, Morphosys and Atara Biotherapeutics: Consultancy; Mustang Bio, Celgene, Pharmacyclics, Gilead, Genentech, Abbvie, TG therapeutics, Beigene, Astra Zeneca, Sunesis, Beigene: Research Funding. Foglietta:Janssen: Honoraria; Gilead: Honoraria. Jaksic:Roche: Honoraria; Janssen: Honoraria; Abbvie: Honoraria. Sportoletti:AbbVie: Honoraria; Janssen: Honoraria. Barr:Morphosys: Consultancy; Gilead: Consultancy; AstraZeneca: Consultancy, Research Funding; Verastem: Consultancy; Seattle Genetics: Consultancy; TG therapeutics: Consultancy, Research Funding; Abbvie/Pharmacyclics: Consultancy, Research Funding; Celgene: Consultancy; Merck: Consultancy; Genentech: Consultancy; Janssen: Consultancy. Ruchlemer:Abbvie Inc: Consultancy, Research Funding. Kersting:Celgene: Other: travel grant; Janssen: Research Funding; Abbvie: Research Funding. Huntington:Pharmacyclics: Honoraria; AbbVie: Consultancy; Novartis: Consultancy; Genentech: Consultancy; DTRM: Research Funding; Celgene: Consultancy, Research Funding; Bayer: Consultancy, Honoraria; Astrazeneca: Honoraria; TG Therapeutics: Research Funding. Herishanu:Roche: Honoraria; Sanofi: Honoraria; Medison: Honoraria; Janssen: Honoraria; Abbvie: Honoraria; AstraZeneca: Honoraria. Jacobs:TG Therapeutics, Inc.: Research Funding; Astra Zeneca: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau; Pharmacyclics: Research Funding, Speakers Bureau; Seattle Genetics: Consultancy; Verastem: Consultancy; Janssen: Consultancy, Speakers Bureau; Genentech: Speakers Bureau; Sanofi Genzyme: Speakers Bureau. Portell:BeiGene: Consultancy, Research Funding; Pharmacyclics: Consultancy; TG Therapeutics: Research Funding; Infinity: Research Funding; Roche/Genentech: Consultancy, Research Funding; Xencor: Research Funding; Bayer: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Kite: Consultancy, Research Funding; Acerta/AstraZeneca: Research Funding; AbbVie: Research Funding. Rambaldi:Sanofi: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Astellas: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); BMS/Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); University of Milan: Current Employment; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support of parent study and funding of editorial support. Received travel support., Research Funding; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support from Gilead.; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). Research grant from Amgen Inc.; Omeros: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). Advisory board and speaker fees from Pfizer.. Brander:Verastem: Consultancy, Honoraria, Other, Research Funding; NCCN: Other; Novartis: Consultancy, Other; Teva: Consultancy, Honoraria; Tolero: Research Funding; NCCN: Other; Novartis: Consultancy, Other; Teva: Consultancy, Honoraria; Tolero: Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; ArQule: Consultancy, Other, Research Funding; Ascentage: Other, Research Funding; AstraZeneca: Consultancy, Honoraria, Other, Research Funding; BeiGene: Other, Research Funding; DTRM: Other, Research Funding; Genentech: Consultancy, Honoraria, Other, Research Funding; Juno/Celgene/BMS: Other, Research Funding; MEI Pharma: Other, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Other, Research Funding; Pfizer: Consultancy, Other; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding. Rossi:Abbvie: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Honoraria; Celgene: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Other: Advisory board; Astellas: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees; Alexion: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Coscia:Karyopharm Therapeutics: Research Funding; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Coombs:Abbvie: Consultancy, Honoraria; Genentech: Honoraria; AstraZeneca: Honoraria; MEI Pharma: Honoraria; LOXO Oncology: Honoraria; Octapharma: Honoraria; Novartis: Honoraria. Schuster:Novartis, Genentech, Inc./ F. Hoffmann-La Roche: Research Funding; AlloGene, AstraZeneca, BeiGene, Genentech, Inc./ F. Hoffmann-La Roche, Juno/Celgene, Loxo Oncology, Nordic Nanovector, Novartis, Tessa Therapeutics: Consultancy, Honoraria. Foà:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Incyte: Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Cuneo:Astra Zeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Bosch:Jansen: Honoraria; Abbvie: Honoraria; Novartis: Honoraria; Astra Zeneca: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Roche: Honoraria. Stamatopoulos:AstraZeneca: Honoraria; Janssen, Gilead, Abbvie: Honoraria, Research Funding. Ghia:Adaptive, Dynamo: Consultancy, Honoraria; Novartis: Research Funding; BeiGene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding; Celgene/Juno: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; MEI: Consultancy, Honoraria; Sunesis: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding; Gilead: Consultancy, Honoraria, Research Funding; ArQule: Consultancy, Honoraria; Acerta/AstraZeneca: Consultancy, Honoraria. Mato:Adaptive: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Consultancy; LOXO: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; TG Therapeutics: Consultancy, Other: DSMB, Research Funding.
- Published
- 2020
188. Poisonous plants of Belize: a mini toxicological review
- Author
-
Chen-Yi Wu, Ayleen Walewska Perez, Israel Coc, Danladi Chiroma Husaini, Cindy J. Bush, and Elsbeth Nerissa Guerra
- Subjects
medicine.medical_specialty ,Geography ,Complementary and alternative medicine ,Agroforestry ,Public health ,fungi ,Toxic plants ,medicine ,food and beverages ,Developing country ,Bibliographic search - Abstract
The global increase in the use of plants for food and medicinal purposes, especially in developing countries, proffers an urgent need for toxicological studies on such plants. Results of extensive toxicological studies tend to provide safety information on toxic plants and help avert public health issues while providing safety guides to the public. Belize is a developing nation, and the only English-speaking country in Central America. More than half of the country is covered by rainforest, and many plants are consumed for food and medicinal purposes mostly without regard to the scientific toxicological characteristics of such plants. To the best of our knowledge, presently no published scientific toxicological reports exist on poisonous plants uniquely native to Belize. A careful bibliographic search was therefore conducted on published scientific reports applicable to plants native to Central America, and unpublished reports on poisonous plants of Belize to describe the toxicological information of such plants. A total of 16 plants from 7 families were identified to be toxic. The identified plants were reviewed for their toxicology. 13 plants were reported to be toxic, 2 plants were shown to be non-toxic, and no scientific studies were found for 1 plant. There is an urgent need to conduct toxicological research on plants native to Belize, especially that many such plants are used for food and medicinal purposes.
- Published
- 2020
189. Promotion of men’s mental health
- Author
-
Anna Mosiołek, Marlena Stradomska, Aleksandra Kielan, Łukasz Święcicki, Bożena Walewska-Zielecka, Mariusz Jaworski, and Jan Chodkiewicz
- Subjects
Gerontology ,Psychiatry and Mental health ,Promotion (rank) ,Health promotion ,media_common.quotation_subject ,Scopus ,Physical health ,Scientific literature ,Psychology ,Mental health ,media_common - Abstract
Introduction: Despite the fact that the knowledge of health differences between males and females is more and more available, it does not always translate into the differentiation of health programmes. Undoubtedly, there is a need for innovative programmes promoting the mental health of men and accounting for male standards. Material and methods: Review of scientific literature concerning mental health promotion, with special regard to recommendation to create programmes of promotion of men’s mental health searched in Pubmed, Scopus and Google Scholar. Results: Health promotion is a process enabling people to increase their control over health and to improve it. Mental health promotion is a rarely discussed branch of health promotion, and its characteristics differ from physical health promotion. Currently, no organised activities are conducted in Poland aiming at the promotion of men’s mental health. Looking at suicide statistics, according to which men take their lives seven times more often than women, it seems essential to design comprehensive activities targeting this specific group. Male-specific determinants of mental health should constitute a reference point for health promoters in the process of designing programmes of mental health promotion. Conclusions: It seems necessary to consider gender factor while designing activities related to mental health promotion. The activities directed to men should be planned according to specific principles. Their implementation may have a positive effect on male participation and involvement in the suggested programme of mental health promotion, and in turn on its efficacy.
- Published
- 2020
190. A religiosidade impacta o binge drinking na adolescência precoce? Um estudo transversal em uma cidade do sudeste do Brasil
- Author
-
Mariana Oliveira Guimarães, Gilberto de Lima Guimarães, Jessica Walewska Rodrigues da Silva, Kátia Kely Bragança de Souza, Raquel Gonçalves Vieira-Andrade, Raquel Conceição Ferreira, and Patrícia Maria Pereira de Araújo Zarzar
- Subjects
Adolescent ,Alcohol Drinking ,Amigos ,Health Policy ,Public Health, Environmental and Occupational Health ,Adolescência ,Binge drinking ,Friends ,Religião ,Adolescence ,Binge Drinking ,Religion ,Cross-Sectional Studies ,Núcleo familiar ,Socioeconomic Factors ,Consumo excessivo de bebidas alcoólicas ,Humans ,Family ,Brazil - Abstract
This study evaluated the association between religiosity and binge drinking in early adolescence. A cross-sectional study was conducted with adolescents aged 10-13 from Belo Horizonte, Brazil. Stratified random sampling was performed considering the administrative district and school year. Adolescents filled an AUDIT-C form, containing questions about religiosity and binge drinking by parents and their best friends. Adolescents’ caregivers answered a form regarding socioeconomic issues. Descriptive analysis, univariate, and multivariate logistic regression were performed. A total of 650 adolescents participated in the study. The frequency of binge drinking was 13.7%. In the adjusted model, religiosity was not associated with binge drinking. The covariates associated were the age of 12-13 years (OR: 1.94; CI95%: 1.06-3.56; p=0.030), maternal binge drinking (OR: 3.12; CI95%: 1.76-5.52; p
- Published
- 2022
191. Nutritional Status Disorders and Selected Risk Factors of Ventilator-Associated Pneumonia (VAP) in Patients Treated in the Intensive Care Ward—A Retrospective Study
- Author
-
Lucyna Ścisło, Elżbieta Walewska, Iwona Bodys-Cupak, Agnieszka Gniadek, and Maria Kózka
- Subjects
Male ,nutritional status disorders ,Critical Care ,VAP ,ventilator-associated pneumonia ,risk factors ,intensive care ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Nutritional Status ,Pneumonia, Ventilator-Associated ,Article ,Intensive Care Units ,Risk Factors ,Medicine ,Humans ,Retrospective Studies - Abstract
Introduction: The development of pneumonia in patients treated in intensive care wards is influenced by numerous factors resulting from the primary health condition and co-morbidities. The aim of this study is the determination of the correlation between nutritional status disorders and selected risk factors (type of injury, epidemiological factors, mortality risk, inflammation parameters, age, and gender) and the time of pneumonia occurrence in patients mechanically ventilated in intensive care wards. Material and method: The study included 121 patients with injuries treated in the intensive care ward who had been diagnosed with pneumonia related to mechanical ventilation. The data were collected using the method of retrospective analysis of patients’ medical records available in the electronic system. Results: Ventilator-associated pneumonia (VAP) occurred more frequently in patients over 61 years of age (40.4%), men (67.8%), after multiple-organ injury (45.5%), and those with a lower albumin level (86%), higher CRP values (83.5%), and leukocytes (68.6%). The risk of under-nutrition assessed with the NRS-2002 system was confirmed in the whole study group. The statistical analysis demonstrated a correlation between the leukocytes level (p = 0.012) and epidemiological factors (p = 0.035) and the VAP contraction time. Patients infected with Staphylococcus aureus had 4% of odds for the development of late VAP in comparison to Acinetobacter baumannii (p < 0.001), whereas patients infected by any other bacteria or fungi had about four times lower odds of the development of late VAP in comparison to Acinetobacter baumannii (p = 0.02). Patients with results in APACHE from 20 to 24 and from 25 to 29 had 13% and 21%, respectively, odds of the development of late VAP in comparison to patients with APACHE II scores ranging from 10 to 19 (respectively, p = 0.006; p = 0.028). Conclusions: The development of VAP is impacted by many factors, the monitoring of which has to be included in prophylactics and treatment.
- Published
- 2022
- Full Text
- View/download PDF
192. Dosimetric comparison of dose calculation accuracy based on standard and extended CT conversion curve for metallic ports in temporary tissue expanders
- Author
-
Aleksandra Bochyńska, Anna Zawadzka, and Agnieszka Walewska
- Published
- 2022
193. Bezpieczeństwo w procedurach chirurgicznych [W: Bezpieczeństwo w wybranych obszarach opieki zdrowotnej]
- Author
-
Ścisło, Lucyna and Walewska, Elżbieta
- Published
- 2022
194. Bezpieczeństwo pacjenta w opiece zdrowotnej
- Author
-
Mirosława Noppenberg, Iwona Bodys-Cupak, Maria Kózka, Maria Budnik-Szymoniuk, Grażyna Cepuch, Izabela Chmiel, Katarzyna Czyżowicz, Agnieszka Gniadek, Alicja Kamińska, Ewa Kawalec-Kajstura, Anna Kosowska, Justyna Kot, Agnieszka Kruszecka-Krówka, Anna Kurowska, Jakub Lickiewicz, Joanna Łatka, Anna Majda, Marta Makara-Studzińska, Iwona Malinowska-Lipień, Dorota Matuszyk, Julia Nawrot, Ilona Nowak-Kózka, Anna Piskorz, Lucyna Płaszewska-Żywko, Grażyna Puto, Aurelia Sega, Izabela Sowińska, Lucyna Ścisło, Elżbieta Walewska, Stanisław Wojtan, Katarzyna Wojtas, Joanna Zalewska-Puchała, and Patrycja Zurzycka
- Published
- 2022
195. Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
- Author
-
Pokorska-Śpiewak, Maria, Kowalik-Mikołajewska, Barbara, Aniszewska, Małgorzata, Pluta, Magdalena, Walewska-Zielecka, Bożena, and Marczyńska, Magdalena
- Published
- 2017
- Full Text
- View/download PDF
196. The influence of hepatitis B and C virus coinfection on liver histopathology in children
- Author
-
Pokorska-Śpiewak, Maria, Kowalik-Mikołajewska, Barbara, Aniszewska, Małgorzata, Walewska-Zielecka, Bożena, and Marczyńska, Magdalena
- Published
- 2015
- Full Text
- View/download PDF
197. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro
- Author
-
Mohamed, Yehia S., Dunnion, Debbie, Teobald, Iryna, Walewska, Renata, and Browning, Michael J.
- Published
- 2012
- Full Text
- View/download PDF
198. Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- Author
-
Mistry, Hema, Nduka, Chidozie, Connock, Martin, Colquitt, Jill, Mantopoulos, Theodoros, Loveman, Emma, Walewska, Renata, and Mason, James
- Published
- 2019
- Full Text
- View/download PDF
199. Avaliação do fungo Penicillium sclerotiorum UCP 1040 na produção de biossurfactante utilizando óleo pós-fritura e milhocina
- Author
-
Freitas, Elizandro Lima, primary, Lima, Sonally de Oliveira, additional, Montero-Rodríguez, Dayana, additional, Andrade, Rosileide Fontenele da Silva, additional, Campos-Takaki, Galba Maria de, additional, and Araújo, Hélvia Walewska Casullo de, additional
- Published
- 2022
- Full Text
- View/download PDF
200. Guideline for the treatment of chronic lymphocytic leukaemia
- Author
-
Walewska, Renata, primary, Parry‐Jones, Nilima, additional, Eyre, Toby A., additional, Follows, George, additional, Martinez‐Calle, Nicolas, additional, McCarthy, Helen, additional, Parry, Helen, additional, Patten, Piers E. M., additional, Riches, John C., additional, Hillmen, Peter, additional, and Schuh, Anna H., additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.